Form 13-F position report

IOVANCE BIOTHERAPEUTICS INC

Reported by GSA CAPITAL PARTNERS LLP

IOVA CUSIP 462260100 Manager CIK 0001362033

Reported 293,959 shares, down 361,359 (55.1%) from the prior quarter.

Reported value 59.8%; share count -55.1% vs. the prior quarter.

Reduced
% of reported 13F value 0.26% This manager · Q3 2026
Shares 293,959 Quarter-end amount reported
Reported value $4,356,000 Fair value at quarter end
Consecutive quarters held 11 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 294000
2022-03-31 280000
2022-06-30 1972000
2022-09-30 774000
2022-12-31 1123000
2023-03-31 1325000
2023-06-30 0
2024-03-31 907000
2024-06-30 0
2024-09-30 242000
2024-12-31 0
2025-03-31 86000
2025-06-30 338000
2025-09-30 172000
2025-12-31 2383000
2026-03-31 1955000
2026-06-30 2726000
2026-09-30 4356000

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for IOVANCE BIOTHERAPEUTICS INC held by GSA CAPITAL PARTNERS LLP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 293,959 -361,359 (-55.1%) 0.26% $4,356,000 2026-11-16
Q2 2026 Added 655,318 +98,233 (17.6%) 0.17% $2,726,000 2026-08-06
Q1 2026 Reduced 557,085 -315,900 (-36.2%) 0.12% $1,955,000 2026-05-08
Q4 2025 Added 872,985 +793,763 (1001.9%) 0.21% $2,383,000 2026-02-06
Q3 2025 Reduced 79,222 -117,385 (-59.7%) 0.01% $172,000 2025-11-07
Q2 2025 Added 196,607 +170,680 (658.3%) 0.02% $338,000 2025-07-22
Q1 2025 New 25,927 +25,927 (0.0%) < 0.01% $86,000 2025-05-08
Q4 2024 Reduced 0 -25,824 (-100.0%) 0 $0 2025-02-07
Q3 2024 New 25,824 +25,824 (0.0%) 0.02% $242,000 2024-11-05
Q2 2024 Reduced 0 -61,225 (-100.0%) 0 $0 2024-08-15
Q1 2024 New 61,225 +61,225 (0.0%) 0.07% $907,000 2024-05-03
Q2 2023 Reduced 0 -216,782 (-100.0%) 0 $0 2023-08-14
Q1 2023 Added 216,782 +40,989 (23.3%) 0.13% $1,325,000 2023-05-12
Q4 2022 Added 175,793 +95,017 (117.6%) 0.14% $1,123,000 2023-02-13
Q3 2022 Reduced 80,776 -97,802 (-54.8%) 0.1% $774,000 2022-11-14
Q2 2022 Added 178,578 +161,755 (961.5%) 0.3% $1,972,000 2022-08-09
Q1 2022 Added 16,823 +1,425 (9.3%) 0.04% $280,000 2022-05-11
Q4 2021 New 15,398 +15,398 (0.0%) 0.04% $294,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

367 managers reported IOVANCE BIOTHERAPEUTICS INC for Q3 2026.

Managers reporting IOVANCE BIOTHERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 37,903,960 +946,279 < 0.01% $561,736,688 9 qtrs
MHR FUND MANAGEMENT LLC Unchanged 28,967,103 0 21.06% $429,292,466 16 qtrs
STATE STREET CORPORATION Reduced 21,695,003 -2,783,265 < 0.01% $321,519,944 38 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 18,396,706 +192,458 < 0.01% $272,639,183 3 qtrs
TWO SIGMA INVESTMENTS LP Reduced 14,964,996 -4,045,701 0.16% $221,781,241 10 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 12,279,882 -2,109,117 < 0.01% $181,987,851 3 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 10,452,242 +127,416 < 0.01% $154,930,479 38 qtrs
D E Shaw & Co Inc Added 9,163,428 +7,020,294 0.06% $135,802,003 28 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 6,238,693 -221,756 0.02% $92,443,267 33 qtrs
The Goldman Sachs Group Inc Reduced 4,937,725 -158,609 < 0.01% $73,177,091 38 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
293,959
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.